PapersPMID:34818350
Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.
What moved
1 findingHow to read these marks →“The patients treated with rosuvastatin in addition to antihypertensives had a significantly lower DBP (MD = −2.12 mmHg; 95% CI = −3.72 to −0.52; Pfixed-effects model = 0.009; I 2 = 0%, Pheterogeneity = 0.97) than the patients treated with antihypertensives alone.”
- Study
- meta-analysis
- Duration
- 8 weeks
- Effect
- −2.12 mean difference, 95% CI −3.72 to −0.52
- Dose studied
- rosuvastatin 20 mg/day
- Population
- Patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents (an ARB, or an ARB plus a calcium channel blocker), compared with the same antihypertensive background alone
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adult patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents versus antihypertensive agents alone
- Participants
- 507
- Comparator
- not stated in the paper / placebo
- Duration
- 56 days
- Endpoints measured
- 4
rosuvastatin